Cargando…
Pneumonia Caused by Community-Acquired Methicillin-Resistant Staphylococcus aureus: Vancomycin or Linezolid?
Autores principales: | Tian, Ye, Huang, Xu, Wu, Li-Juan, Yi, Li, Li, Min, Gu, Si-Chao, Guo, Dong-Jie, Zhan, Qing-Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085849/ https://www.ncbi.nlm.nih.gov/pubmed/30082534 http://dx.doi.org/10.4103/0366-6999.238139 |
Ejemplares similares
-
Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
por: Patel, Dipen A, et al.
Publicado: (2014) -
Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy
por: Pletz, Mathias W, et al.
Publicado: (2010) -
Evolution of Multi-Resistance to Vancomycin, Daptomycin, and Linezolid in Methicillin-Resistant Staphylococcus aureus Causing Persistent Bacteremia
por: Chen, Chih-Jung, et al.
Publicado: (2020) -
An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany
por: Patel, Dipen A, et al.
Publicado: (2014) -
In vitro antibacterial effects of Tanreqing injection combined with vancomycin or linezolid against methicillin-resistant Staphylococcus aureus
por: Yang, Weifeng, et al.
Publicado: (2018)